Blood Cancer Journal seeks to publish articles of the highest quality related to hematologic malignancies and related disorders. The Journal will consider for publication original research, reviews, guidelines and letters that are considered to be of high impact in the field.Topics of particular interest include, but are not limited to, the following:Preclinical studies of new compounds, especially those that provide mechanistic insightsClinical trials and observationsReviews related to new drugs and current management of hematologic malignanciesNovel observations related to new mutations, molecular pathways, and tumor genomics.
《血液癌症杂志》旨在发表与血液恶性肿瘤和相关疾病相关的最高质量的文章。期刊将考虑发表在该领域具有高度影响力的原创研究、综述、指南和信件。特别感兴趣的主题包括但不限于以下内容：新化合物的临床前研究，特别是提供机制见解的化合物临床试验和观察与血液恶性肿瘤的新药和当前管理相关的综述与新突变、分子途径和肿瘤基因组学相关的新观察。
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0198-4
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0200-1
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0170-3
Molecular signatures of multiple myeloma progression through single cell RNA-Seq
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-018-0160-x
The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-018-0164-6
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-018-0154-8
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0254-0
Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0185-9
Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0177-9
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0173-0
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0255-z
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0209-5
Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0264-y
Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0242-4
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0178-8
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0181-0
Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-018-0168-2
Oprozomib in patients with newly diagnosed multiple myeloma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0232-6
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0206-8
Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0182-z
Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0248-y
Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0224-6
Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0237-1
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0226-4
Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0252-2
Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0210-z
Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0203-y
Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0238-0
The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0188-6
World Health Organization class-independent risk categorization in mastocytosis
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0189-5
Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0195-7
Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0261-1
A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0180-1
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-018-0169-1
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0176-x
Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0253-1
Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0184-x
Expression of the long non-coding RNA TCL6 is associated with clinical outcome in pediatric B-cell acute lymphoblastic leukemia
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0258-9
Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0172-1
Validation of the Mayo alliance prognostic system for mastocytosis
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0179-7
Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0186-8
Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0229-1
Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0259-8
The ATRA-21 gene-expression model predicts retinoid sensitivity in CEBPA double mutant, t(8;21) and inv(16) AML patients
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0241-5
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0235-3
Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0249-x
Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0243-3
CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0171-2
Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
来源期刊：Blood Cancer JournalDOI：10.1038/s41408-019-0214-8
